Andres-KleinUniversidad del Desarrollo (Chile)

Prof. Andrés Klein’s research interests include uncovering the genetic and cellular basis of phenotypic variability as a way for identifying novel therapeutic targets for rare and common genetic diseases. To this end he uses population based approached in both mice and humans. His work has led to the discovery of potential treatments for two genetic diseases (Niemann-Pick C and neuropathic Gaucher disease), using FDA-approved drugs.

Andrés Klein received his B.Sc in Biochemistry and his PhD in Cellular and Molecular Biology at the Pontificia Universidad Católica de Chile. Dr. Klein did a postdoc at Stanford University (2009-2011) and a second postdoc (2011-2015) at the Weizmann Institute of Science in Israel. After working for a couple of years at the Telethon Institute of Genetics and Medicine (TIGEM) in Italy he joined the Centre for Genetics and Genomics at the Universidad del Desarrollo (UDD) in Chile as a Faculty member, where he is applying cutting edge technologies, such as exome sequencing plus multi-omics, for the identification of modifier genes of disease progression and biomarkers.

Dr. Klein has been endorsed by several institutions including Pew Charitable Trust (2009-2011), Ara Parseghian Medical Research Foundation (2009-2011), and the UK Gaucher Association (2011-2013). Prof. Klein was awarded with the young Chilean innovator prize by MIT technology reviews (2013) and he was selected as one of the top 100 young Chilean leaders of 2013. He has received grants from several international organizations including the Rosetrees of Trust (UK), Cure & Action for Tay-Sachs disease (UK) and Horizon 2020 (EU).

Sign up for our eNewsletter today!


First Name

Thanks for your patience while the donation form loads!

Cures Within Reach

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes.  CWR is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Wednesday the 23rd. Copyright 2018 Cures Within Reach.